Advertisement

Der Urologe

, Volume 57, Issue 6, pp 729–730 | Cite as

Neue Therapieoption – Apalutamid beim nicht fernmetastasierten kastrationsresistenten Prostatakarzinom

Journal Club
  • 40 Downloads

New treatment option—apalutamide for nonmetastatic, castration-resistant prostate cancer

Notes

Interessenkonflikt

B. Hadaschik ist im Steering Committee der SPARTAN-Studie und übt Beratertätigkeiten für BMS, Janssen und Sanofi aus. Referententätigkeiten erfolgen für Astellas, Bayer, BMS, Curagita, Janssen, MedCom, Pfizer und Pierre Fabre. A. Panic gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    LATITUDE Investigators, Fizazi K, Tran NP, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360CrossRefGoogle Scholar
  2. 2.
    Hussain M, Fizazi K, Said F (2018) ASCO GU 2018: first presentation - PROSPER: safety and efficacy study of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). AUA 2018.Google Scholar
  3. 3.
    STAMPEDE investigators, James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177CrossRefGoogle Scholar
  4. 4.
    Smith MR, Antonarakis ES, Ryan CJ et al (2016) Phase 2 study of the safety and anti-tumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol 70:963–970CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Smith MR et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800–3806CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schwarzenboeck SM, Rauscher I, Bluemel C et al (2017) PSMA ligands for PET imaging of prostate cancer. J Nucl Med 58:1545–1552CrossRefPubMedGoogle Scholar
  7. 7.
    Sweeney CJ, Chen YH, Liu G et al (2016) Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Ann Oncol 27:243–265CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Urologie, Uroonkologie und KinderurologieUniversitätsklinikum Essen (AÖR)EssenDeutschland

Personalised recommendations